1. |
A nicotine vaccine for smoking cessation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Antiasthmatic drug use increasing in Spain |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Rosuvastatin surpasses atorvastatin across full dose range |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 7-8
Raewyn Poole,
Preview
|
|
摘要:
Rosuvastatin ['Crestor'] is significantly more effective than atorvastatin ['Lipitor'] in reducing LDL-cholesterol levels in patients with hypercholesterolaemia, according to results from a study presented at the 2002 European Society of Cardiology (ESC) congress [Berlin, Germany; August-September 2002]. Furthermore, significantly greater improvements in the levels of non-HDL and total cholesterol, as well as apolipoprotein B levels were observed in rosuvastatin, compared with atorvastatin, recipients across the dose range evaluated. At higher doses, rosuvastatin was shown to provide additional benefit, compared with atorvastatin, through significantly greater increases in HDL-cholesterol and apolipoprotein A-I levels.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
XENDOS: orlistat can prevent diabetes in obese patients |
|
Inpharma Weekly,
Volume &NA;,
Issue 1359,
2002,
Page 11-12
Rosalind Black,
Preview
|
|
摘要:
Treatment with the lipase inhibitor orlistat ['Xenical'] in addition to lifestyle intervention significantly delays the development of type 2 diabetes mellitus in obese patients, according to results from the ground-breaking XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study presented at the 9th International Congress on Obesity [São Paulo, Brazil; August 2002]. Furthermore, the study also demonstrated that orlistat was effective in long-term maintenance of weight loss. XENDOS is the first 4-year study of a weight management agent, and is also the first to investigate the use of such an agent for the prevention of diabetes.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|